drugset / Trial / NCT04789408
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
Timeline
- Start
- 2021-07-19
- Primary completion
- 2024-05-18
- Completion
- 2024-05-18
Outcome
Outcome not reported
Stopped: “Study was terminated due to futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KITE-222 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |